Glucotrack Seeks Shareholder Approval for Reverse Split and Warrant Inducement to Avoid Nasdaq Delisting
GCTK sits 67% above its 52-week low of $0.291 on elevated volume (3.1× avg).
Summary
Glucotrack's definitive proxy asks shareholders to approve a 1-for-30 reverse stock split to avoid Nasdaq delisting and a warrant inducement that could issue up to 6.2 million shares, adding massive dilution risk. The filing also discloses a new CEO and board after the recent reverse merger with Lokahi Therapeutics.
Key Events · Corporate Governance and Compliance · GCTK
-
Reverse Stock Split Proposed
Shareholders will vote on a 1-for-30 reverse stock split designed to lift the stock price above $1.00 and preserve the Nasdaq listing. At the maximum ratio, outstanding shares would shrink from 7.7 million to about 257,000.
-
Warrant Inducement Could Add 6.2M Shares
Proposal 5 seeks approval to reprice existing warrants and issue new inducement warrants, potentially adding up to 6,201,546 shares—an 80% increase over current outstanding shares—to raise cash but heavily diluting existing holders.
-
Nasdaq Delisting Risk
The company has received two delisting notices for failing to meet the minimum bid price and stockholders' equity requirements. The reverse split is critical to regaining compliance.
-
New CEO and Board After Reverse Merger
Erik Emerson was appointed CEO and director in July 2026 following the reverse merger with Lokahi Therapeutics, which now controls 90% of the company. The proxy reflects the new board composition.
Analysis · GCTK · Industrial Applications And Services
To keep its stock above $1 and raise cash, Glucotrack is asking shareholders to approve a 1-for-30 reverse stock split and a warrant inducement that could issue up to 6.2 million shares. The company faces a going-concern warning, two delisting notices, and has just closed a reverse merger that handed 90% control to Lokahi Therapeutics. The reverse split represents a last-ditch effort to maintain its Nasdaq listing, while the warrant inducement aims to bring in capital by repricing existing warrants and issuing new ones—but at the cost of severe dilution for current holders. The proxy also reveals a new CEO and board following the merger, underscoring the complete transformation of the company.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.7% of the 583 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GCTK was trading at $0.48 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.1M. The 52-week trading range was $0.29 to $14.14. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.